ERBB2 and gastric cancer: Trastuzumab is a molecular-targeting drug for HER2; and as the result of the ToGA trial, the addition of trastuzumab to chemotherapy has become the standard treatment for advanced HER2-positive GC patients and is the only anti-HER2 agent approved for treatment of such patients nowadays [6,7].